bovin
coronaviru
bcv
caus
pathogen
diarrhea
cattl
caus
signific
econom
loss
worldwid
traven
et
al
bcv
member
famili
coronavirida
divid
three
group
initi
basi
serolog
related
recent
basi
genom
sequenc
similar
wu
et
al
bcv
conveni
classifi
two
group
one
enter
type
isol
intestin
tract
respiratori
type
isol
upper
respiratori
tract
hasoksuz
et
al
recent
identifi
human
sever
acut
respiratori
syndrom
viru
classifi
group
four
coronavirida
famili
infect
bcv
caus
sever
diarrhea
neonat
calv
winter
dysenteri
cattl
although
mani
vaccin
trial
carri
mebu
et
al
myer
snodgrass
freitag
et
al
bcv
virion
detect
rel
high
rate
throughout
year
nasal
drip
fecal
sampl
vaccin
anim
even
though
viru
neutral
antibodi
detect
sera
clark
bcv
therefor
recogn
persist
infect
natur
consid
transmiss
profil
bcv
infect
seem
difficult
erad
bcv
infect
immunolog
treatment
fact
field
studi
bcv
shown
vaccin
effect
prevent
diarrhea
calv
et
al
heckert
et
al
efficaci
question
prevent
infect
pathogen
agent
livestock
base
differ
strategi
use
human
anim
suffer
sever
infecti
diseas
sacrif
mainten
healthi
anim
herd
polyphenol
catechin
green
tea
contain
sever
isom
includ
gallat
egcg
gallat
egcg
major
compon
yamaguchi
et
al
compound
radic
scaveng
action
chen
et
al
antimutagen
activ
kada
et
al
yen
chen
activ
kawas
et
al
yokozawa
et
al
broad
spectrum
antimicrobi
activ
bacteria
amarowicz
et
al
yee
koo
sakanaka
okada
fungi
hirasawa
takada
virus
egcg
shown
antivir
effect
envelop
virus
influenza
viru
nakayama
et
al
haneda
et
al
yamaguchi
et
al
kawai
et
al
viru
ebv
taniguchi
et
al
chang
et
al
report
egcg
also
potent
inactiv
activ
enter
type
bcv
bovin
kidney
mdbk
cell
american
type
cultur
collect
rockvil
md
usa
use
viral
propag
maintain
eagl
minimum
essenti
medium
mem
sigma
st
loui
mo
usa
supplement
vv
fetal
bovin
serum
gentamicin
cultur
medium
gibco
brl
grand
island
ny
usa
kakegawa
strain
bcv
akashi
et
al
obtain
nippon
zenyaku
kogyo
koriyama
japan
passag
mdbk
cell
epigallocatechin
gallat
obtain
pharma
food
intern
kyoto
japan
order
obtain
distinct
data
antivir
effect
egcg
examin
cytotox
effect
egcg
mdbk
cell
mdbk
cell
cultiv
presenc
variou
concentr
egcg
day
cytotox
effect
egcg
mdbk
cell
examin
use
cell
count
dojin
kumamoto
japan
base
reduct
tetrazolium
salt
intracellular
dehydrogenas
viabl
cell
ishiyama
et
al
viru
titrat
perform
use
unit
pfu
assay
mdbk
cell
mdbk
cell
seed
onto
well
micropl
densiti
cell
cultur
confluenc
reach
confluent
monolay
wash
twice
salin
pb
ph
viru
inocul
cell
monolay
incub
min
carbon
subsequ
cell
wash
pb
remov
unadsorb
virus
overlaid
cultur
medium
contain
wv
agar
sigma
incub
day
plaqu
visual
overlay
neutral
red
mem
contain
agar
count
plaqu
reduct
assay
perform
confluent
monolay
mdbk
cell
infect
bcv
multipl
infect
approxim
pfucel
antivir
effect
egcg
evalu
mdbk
cell
inocul
bcv
ii
mdbk
cell
inocul
bcv
prepar
mdbk
cell
confluent
monolay
wash
twice
pb
incub
cultur
medium
contain
egcg
indic
concentr
min
carbon
prepar
bcv
viru
incub
cultur
medium
contain
egcg
indic
concentr
min
inocul
mdbk
cell
case
mixtur
viru
egcg
incub
min
untreat
mdbk
cell
incub
treat
bcv
respect
incub
min
follow
wash
twice
pb
cultiv
day
carbon
result
number
plaqu
count
compar
number
plaqu
form
cell
cell
inocul
viru
hemagglutin
ha
indic
cell
prepar
follow
suspens
mous
erythrocyt
salin
fix
glutaraldehyd
final
concentr
wv
h
follow
wash
twice
pb
titrat
ha
activ
suspens
cell
pb
ad
serial
twofold
dilut
bcv
specimen
incub
min
room
temperatur
reciproc
highest
dilut
gave
posit
agglutin
taken
ha
titer
sampl
test
least
triplic
data
statist
analyz
use
dunnett
test
result
express
mean
standard
deviat
p
consid
signific
shown
fig
signific
differ
number
untreat
viabl
cell
egcg
concentr
less
henc
experi
evalu
antivir
effect
egcg
carri
present
studi
egcg
concentr
less
next
examin
inhibitori
effect
egcg
propag
bcv
mdbk
cell
treat
viru
mdbk
cell
egcg
concentr
show
cytotox
effect
mdbk
cell
shown
fig
number
plaqu
form
virus
reduc
wherea
similar
reduct
number
plaqu
also
found
mdbk
cell
treat
egcg
manner
howev
number
plaqu
form
virus
significantli
lower
form
mdbk
cell
except
concentr
p
next
experi
carri
see
whether
interact
egcg
molecul
viru
particl
manner
respons
antivir
effect
egcg
shown
fig
number
plaqu
found
specimen
examin
effect
decreas
compar
found
furthermor
number
plaqu
significantli
decreas
manner
p
contrast
interact
egcg
bcv
particl
occur
effect
min
incub
period
signific
reduct
number
plaqu
found
among
preincub
time
point
result
shown
fig
suggest
extent
antivir
activ
egcg
simpli
depend
condit
reaction
egcg
bcv
particl
examin
direct
action
egcg
spike
glycoprotein
determin
ha
activ
shown
fig
notic
ha
activ
follow
treatment
egcg
markedli
decreas
compar
follow
treatment
egcg
result
roughli
coincid
plaqu
reduct
profil
shown
present
studi
focus
egcg
candid
reagent
bcv
infect
livestock
anim
shown
fig
egcg
proven
activ
bcv
pretreat
egcg
concentr
show
cytotox
effect
mdbk
cell
effect
egcg
depend
period
temperatur
pretreat
bcv
contrast
effect
egcg
prolifer
bcv
mdbk
cell
effect
found
virus
suggest
antivir
effect
egcg
mainli
result
interact
egcg
molecul
viru
particl
fig
bovin
coronaviru
four
major
structur
protein
spike
glycoprotein
hemagglutinin
acetylesteras
glycoprotein
membran
glycoprotein
nucleocapsid
phosphoprotein
lai
cavanagh
spike
glycoprotein
accept
major
candid
protein
recogn
viral
receptor
cell
surfac
popova
zhang
adsorpt
spike
glycoprotein
may
cleav
one
site
host
proteas
yield
protein
attach
protein
bind
receptor
molecul
cell
membran
protein
undergo
conform
chang
enabl
fuse
membran
target
cell
first
step
viral
infect
bind
viru
target
cell
hemagglutin
hemadsorpt
use
assay
studi
interact
although
erythrocyt
target
cell
viru
infect
furthermor
recent
studi
shown
protein
ha
activ
clark
zelu
et
al
order
confirm
egcg
act
first
step
viral
infect
direct
effect
egcg
ha
activ
bcv
examin
shown
fig
ha
activ
decreas
decreas
egcg
concentr
temperatur
reaction
mixtur
bcv
egcg
thu
strongli
suggest
antivir
activ
egcg
depend
interact
egcg
molecul
protein
bcv
mechan
antivir
effect
egcg
virus
human
ebv
may
simpl
case
egcg
inhibit
bind
viral
protein
molecul
bind
kawai
et
al
also
destroy
viru
particl
bind
surfac
viral
envelop
yamaguchi
et
al
egcg
also
act
inhibitor
revers
transcriptas
viral
transcript
activ
viral
proteas
nakan
ono
nanc
shearer
case
ebv
egcg
block
initi
ebv
lytic
cascad
target
cell
cell
infect
persist
viru
inhibit
transcript
ebv
gene
chang
et
al
inhibit
adsorpt
influenza
viru
also
ha
spike
protein
viral
envelop
canin
kidney
cell
egcg
previous
report
studi
nakayama
et
al
found
egcg
quickli
bind
viru
agglutin
protein
specif
antibodi
viru
block
adsorpt
viru
canin
kidney
cellular
surfac
observ
electron
microscopi
gener
viral
envelop
compos
cellular
phospholipid
compon
hiv
except
known
egcg
neg
charg
capabl
bind
viral
receptor
cell
surfac
stein
et
al
ikigai
et
al
witvrouw
de
clercq
yamaguchi
et
al
present
studi
bcv
propag
suppress
egcg
cell
cultur
min
wash
twice
pb
viru
inocul
howev
direct
reactiv
egcg
mdbk
cell
might
strong
direct
reactiv
egcg
bcv
number
plaqu
viru
significantli
lower
mdbk
cell
even
egcg
concentr
fig
find
support
result
ha
inhibit
assay
ha
activ
bcv
decreas
half
neg
control
presenc
egcg
concentr
fig
result
demonstr
interact
egcg
spike
glycoprotein
bcv
may
play
pivot
role
process
inhibitori
effect
egcg
although
examin
requir
conclud
effect
egcg
exert
interact
egcg
bcv
particl
first
step
viral
infect
result
antivir
activ
hiv
ebv
influenza
viru
bcv
suggest
mechan
antivir
effect
egcg
differ
viru
viru
depend
target
cell
virus
propag
present
studi
shown
antivir
activ
egcg
manner
suggest
possibl
egcg
inhibit
bcv
effect
bovin
intestin
tract
temperatur
approxim
respiratori
tract
although
experi
need
elucid
whether
egcg
abil
prevent
infect
bcv
vivo
present
studi
show
egcg
repres
potenti
inhibitor
bcv
infect
